 |
市場調查報告書
商品編碼
1396137
全球抗體生產市場規模、佔有率、成長分析（依產品類型、依流程分類）- 產業預測，2023-2030 年Global Antibody Production Market Size, Share, Growth Analysis, By Type(Monoclonal Antibody, and Polyclonal Antibody), By Process(Upstream Processing, and Downstream Processing) - Industry Forecast 2023-2030 |
||||||
2021年抗體生產市場規模為145.3億美元，預計將從2022年的164億美元成長到2030年的433億美元，預測期間（2023-2030年）複合年成長率為12.9%。
抗體生產市場旨在滿足用於標靶治療、診斷和疫苗開發的抗體不斷成長的需求。生物技術的進步和對分子水平疾病的更好理解正在增加對特異性和有效抗體的需求。這些抗體已成為研究疾病機制、辨識生物標記和推進個人化醫療方法的重要工具。抗體生產市場的關鍵促進因素是慢性病和感染疾病的日益流行，以及對標靶治療和診斷的需求不斷增加。抗體在治療癌症、自體免疫疾病、感染疾病等方面顯示出有希望的結果。對精準醫療和個體化治療策略的日益重視進一步推動了市場成長。儘管存在課題，抗體生產市場仍存在一些機會。重組 DNA 技術和高通量篩檢方法的發展等技術進步正在提高抗體生產的效率和擴充性。全球抗體生產市場為診斷、治療和研究提供重要工具，在醫療保健和製藥領域中發揮重要作用。市場擴張是由對標靶治療、診斷和個人化醫療方法的追求不斷成長的需求所推動的。儘管面臨課題，技術進步和不斷變化的醫療保健需求正在為抗體生產市場的創新和成長創造機會。
本報告的目標區隔市場
全球抗體生產市場根據類型、製程和地區進行區隔。根據類型分類，市場分為單株抗體和多克隆抗體。依工藝，市場分為上游工藝和下游工藝。依地區分類，市場分為北美、歐洲、亞太地區、中東和非洲以及拉丁美洲。
促進因素
慢性病流行
慢性病的普及和標靶治療的普及正在增加對基於抗體的治療的需求。抗體以其特異性和功效而聞名，在多種疾病的治療中發揮重要作用，包括癌症、自體免疫疾病和感染疾病。單株抗體 (mAb) 的出現催生了多種基於抗體治療方法的重磅藥物，並體現了治療領域的變革方法。
生物技術的進步
生物技術和生物製藥研究的不斷進步加快了抗體生產過程並提高了產品品質標準。包括基因工程、細胞培養技術和高通量篩檢方法的技術突破促進了新型抗體產品的創造。這些進步使抗體生產更有效率、擴充性且更具成本效益。
抑制因素
生產成本高
複雜的工藝、大量的研究和開發工作以及對抗體開發和生產的大規模生產設施的需求導致了高昂的相關成本。這些不斷上漲的成本是一個主要限制因素，特別是對於中小企業來說。抗體生產的高成本阻礙了基於抗體的療法的獲取和可用性，這對市場成長構成了課題。
嚴格的監管要求
抗體生產市場受到美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構制定的嚴格監管要求的監管。遵守這些法規對於確保抗體醫藥品的安全、品質和功效至關重要。然而，複雜的法律規範和嚴格的核准程序可能會給行業參與者帶來課題，並導致產品開發和商業化的延遲。
市場趨勢：
對個人化醫療的日益關注
醫療保健行業擴大採用個人化醫療，這種趨勢與抗體生產是一致的，允許為個別患者量身定做治療方法。基因組和蛋白質組技術的進步正在促進特定疾病標記物的識別，為產生針對這些標記物的抗體鋪平道路，並推動向個人化醫療的轉變。
生物相似藥的採用增加
此外，生物相似藥的採用正在增加。生物相似藥是一種與已確定的參考生物製藥非常相似的生物製藥。對具有成本效益的治療方法的追求正在刺激生物相似藥抗體的開發和接受度。隨著某些著名生物製藥製劑的專利到期，市場上生物相似藥抗體的產量激增。這一趨勢將促進競爭，拓寬市場前景，並改善基於抗體的治療的可及性。
目錄
- 執行摘要
- 調查方法
- 母市場分析
- 主要市場考察
- 技術分析
- 價格分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 智慧財產權分析
- 貿易分析
- Start-Ups分析
- 原料分析
- 創新矩陣
- 研發線產品分析
- 總體經濟指標
- 主要投資分析
- 關鍵成功因素
- 競爭程度
- 市場動態及展望
- 市場動態
- 促進因素
- 機會
- 抑制因素
- 任務
- 監管形勢
- 波特的分析
- 對未來中斷的特殊考察
- 市場動態
- 全球抗體生產市場：依類型
- 市場概況
- 單株抗體
- 多克隆抗體
- 全球抗體生產市場：依製程分類
- 市場概況
- 上游過程
- 下游工藝
- 全球抗體生產市場規模：依地區分類
- 市場概況
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲國家地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 其他拉丁美洲地區
- 中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區
- 競爭形勢
- 前5名企業對比
- 主要企業市場定位（2021年）
- 主要市場參與者所採取的策略
- 關鍵成功策略
- 近期市集活動
- 主要企業市場佔有率（2021年）
- 主要企業簡介
- Roche（Switzerland）
- Genmab（Denmark）
- Amgen（US）
- Biogen（US）
- Johnson & Johnson（US）
- AbbVie（US）
- AstraZeneca（UK）
- Novartis（Switzerland）
- Pfizer（US）
- Sanofi（France）
- Merck & Co.（US）
- Gilead Sciences（US）
- Celgene（US）
- BioMarin Pharmaceutical（US）
- Shire（Ireland）
- Alexion Pharmaceuticals（US）
- Teva Pharmaceuticals（Israel）
- Allergan（US）
- Bristol Myers Squibb（US）
- Novo Nordisk（Denmark）
Antibody production Market size was valued at USD 14.53 Billion in 2021 and is poised to grow from USD 16.40 Billion in 2022 to USD 43.30 Billion by 2030, at a CAGR of 12.9% during the forecast period (2023-2030).
The antibody production market aims to fulfill the increasing demand for antibodies utilized in the development of targeted therapies, diagnostics, and vaccines. With advancements in biotechnology and a growing understanding of diseases at the molecular level, there is a rising requirement for specific and effective antibodies. These antibodies serve as essential tools for studying disease mechanisms, identifying biomarkers, and advancing personalized medicine approaches. An essential driving factor for the antibody production market is the escalating prevalence of chronic and infectious diseases, fostering demand for targeted therapies and diagnostics. Antibodies have demonstrated promising outcomes in treating conditions like cancer, autoimmune disorders, and infectious diseases. The market's growth is further propelled by the expanding emphasis on precision medicine and personalized treatment strategies. Despite existing challenges, several opportunities exist within the antibody production market. Technological progress, including the development of recombinant DNA technology and high-throughput screening methods, has enhanced the efficiency and scalability of antibody production. The global antibody production market plays a crucial role in the healthcare and pharmaceutical sectors by providing essential tools for diagnostics, therapeutics, and research. The market's expansion is steered by the growing demand for targeted therapies, diagnostics, and the pursuit of personalized medicine approaches. While challenges persist, ongoing technological advancements and evolving healthcare needs create opportunities for innovation and growth in the antibody production market.
Segments covered in this report
The global antibody production market is segmented on the basis of type, process, and region. Based on classification by type, the market is segmented into Monoclonal Antibody, and Polyclonal Antibody. By Process, the market is segmented into Upstream Processing, Downstream Processing. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers:
prevalence of chronic diseases
The escalating prevalence of chronic diseases and the growing adoption of targeted therapies have generated a heightened demand for antibody-based therapeutics. Antibodies, known for their specificity and efficacy, play a crucial role in treating a spectrum of diseases, including cancer, autoimmune disorders, and infectious diseases. The advent of monoclonal antibodies (mAbs) exemplifies a transformative approach in the treatment landscape, yielding several blockbuster drugs rooted in antibody-based therapies.
Advancements in Biotechnology
Ongoing progress in biotechnology and biopharmaceutical research has expedited antibody production processes and elevated product quality standards. Technological breakthroughs, encompassing genetic engineering, cell culture techniques, and high-throughput screening methods, have facilitated the creation of novel antibody-based products. These advancements collectively contribute to heightened efficiency, scalability, and cost-effectiveness in antibody production.
Restraints:
High Production Costs
The intricate processes, substantial research and development endeavors, and the need for extensive manufacturing facilities in the development and production of antibodies result in high associated costs. These elevated costs can pose a significant constraint, especially for smaller and medium-sized enterprises. The expense-intensive nature of antibody production hinders the accessibility and affordability of antibody-based therapies, presenting a challenge to the growth of the market.
Stringent regulatory requirements
The antibody production market is governed by stringent regulatory requirements set forth by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adherence to these regulations is essential to guarantee the safety, quality, and efficacy of antibody-based products. Nevertheless, the intricate regulatory framework and demanding approval procedures can present challenges for industry participants, potentially causing delays in product development and commercialization.
Market Trends:
Increasing Focus on Personalized Medicine
The healthcare sector is increasingly embracing personalized medicine, a trend that aligns with antibody production by enabling tailored therapies for individual patients. Advances in genomic and proteomic technologies have facilitated the identification of specific disease markers, paving the way for the creation of antibodies targeting these markers, thus fueling the shift towards personalized medicine.
Rising Adoption of Biosimilars
Additionally, there's a growing adoption of biosimilars, which are biological products highly akin to established reference biologic drugs. The pursuit of cost-effective treatment options has spurred the development and acceptance of biosimilar antibodies. As patents expire for certain prominent biologic drugs, the market is witnessing an upsurge in biosimilar antibody production. This trend promotes competition, broadens market prospects, and enhances accessibility to antibody-based therapies.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Market Dynamics
- Global Antibody Production Market by Type
- Market Overview
- Monoclonal Antibody
- and Polyclonal Antibody
- Global Antibody Production Market by Process
- Market Overview
- Upstream Processing
- and Downstream Processing
- Global Antibody Production Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genmab (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioMarin Pharmaceutical (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shire (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alexion Pharmaceuticals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceuticals (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche (Switzerland)
抗體發現市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按抗體類型、性質、服務、最終用戶和地理位置
全球抗體藥物複合體市場：2024年至2029年預測
抗體生產市場：按產品類型、製程和最終用戶分類 - 2024-2030 年全球預測
抗體藥物複合體契約製造市場：按連結器、條件和最終用途分類 - 2024-2030 年全球預測
研究抗體的全球市場
多克隆抗體市場：依類型、來源、應用、最終用戶、地區![抗體治療市場- 按類型[單株抗體(mAb) {腫瘤、自體免疫疾病、傳染病}、抗體藥物偶聯物(ADC)]、按最終用途（醫院、專科中心）分類- 全球預測，2023年- 2032 年](/sample/img/cover/42/1416204.png)
抗體治療市場- 按類型[單株抗體(mAb) {腫瘤、自體免疫疾病、傳染病}、抗體藥物偶聯物(ADC)]、按最終用途（醫院、專科中心）分類- 全球預測，2023年- 2032 年
抗體藥物偶聯物市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測
多株抗體抗體市場規模 - 按產品（一抗、二抗）、應用、給藥途徑（IV、SC）、來源（兔、山羊、小鼠、人類）、最終用戶、全球預測（2023-2032）
多克隆抗體市場報告：2030 年趨勢、預測和競爭分析